No biomarker No biomarker	Triple Negative Breast Cancer Triple Negative Breast Cancer	No biomarker No biomarker	Triple Negative Breast Cancer Triple Negative Breast Cancer	sacituzumab govitecan-hziy Sensitive: A1 - Approval Gilead Press Release - 4 weeks	sacituzumab govitecan-hziy Sensitive: A1 - Approval Gilead Press Release - 4 weeks
PD-L1 expression PD-L1 expression	Triple Negative Breast Cancer Triple Negative Breast Cancer	PD-L1 expression PD-L1 expression	Triple Negative Breast Cancer Triple Negative Breast Cancer	atezolizumab Sensitive: A1 - Approval	atezolizumab Sensitive: A1 - Approval
PD-L1 expression PD-L1 expression	Triple Negative Breast Cancer Triple Negative Breast Cancer	PD-L1 expression PD-L1 expression	Triple Negative Breast Cancer Triple Negative Breast Cancer	pembrolizumab Sensitive: A1 - Approval	pembrolizumab Sensitive: A1 - Approval
No biomarker No biomarker	Triple Negative Breast Cancer Triple Negative Breast Cancer	No biomarker No biomarker	Triple Negative Breast Cancer Triple Negative Breast Cancer	pembrolizumab Sensitive: A1 - Approval	pembrolizumab Sensitive: A1 - Approval
No biomarker No biomarker	Triple Negative Breast Cancer Triple Negative Breast Cancer	No biomarker No biomarker	Triple Negative Breast Cancer Triple Negative Breast Cancer	CaT Sensitive: A2 - Guideline	CaT Sensitive: A2 - Guideline
BRCA2 mutation BRCA2 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA2 mutation BRCA2 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	cisplatin Sensitive: A2 - Guideline	cisplatin Sensitive: A2 - Guideline
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	cisplatin Sensitive: A2 - Guideline	cisplatin Sensitive: A2 - Guideline
BRCA2 mutation BRCA2 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA2 mutation BRCA2 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	carboplatin Sensitive: A2 - Guideline	carboplatin Sensitive: A2 - Guideline
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	carboplatin Sensitive: A2 - Guideline	carboplatin Sensitive: A2 - Guideline
BRCA2 mutation BRCA2 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA2 mutation BRCA2 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	gemcitabine Sensitive: A2 - Guideline	gemcitabine Sensitive: A2 - Guideline
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	gemcitabine Sensitive: A2 - Guideline	gemcitabine Sensitive: A2 - Guideline
BRCA2 mutation BRCA2 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA2 mutation BRCA2 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	capecitabine Sensitive: A2 - Guideline	capecitabine Sensitive: A2 - Guideline
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	capecitabine Sensitive: A2 - Guideline	capecitabine Sensitive: A2 - Guideline
BRCA2 mutation BRCA2 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA2 mutation BRCA2 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	vinorelbine tartrate Sensitive: A2 - Guideline	vinorelbine tartrate Sensitive: A2 - Guideline
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	vinorelbine tartrate Sensitive: A2 - Guideline	vinorelbine tartrate Sensitive: A2 - Guideline
BRCA2 mutation BRCA2 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA2 mutation BRCA2 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	eribulin mesylate Sensitive: A2 - Guideline	eribulin mesylate Sensitive: A2 - Guideline
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	eribulin mesylate Sensitive: A2 - Guideline	eribulin mesylate Sensitive: A2 - Guideline
BRCA2 mutation BRCA2 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA2 mutation BRCA2 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	pegylated liposomal doxorubicin Sensitive: A2 - Guideline	pegylated liposomal doxorubicin Sensitive: A2 - Guideline
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	pegylated liposomal doxorubicin Sensitive: A2 - Guideline	pegylated liposomal doxorubicin Sensitive: A2 - Guideline
BRCA2 mutation BRCA2 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA2 mutation BRCA2 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	paclitaxel Sensitive: A2 - Guideline	paclitaxel Sensitive: A2 - Guideline
BRCA2 mutation BRCA2 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA2 mutation BRCA2 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	olaparib Sensitive: A2 - Guideline	olaparib Sensitive: A2 - Guideline
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	olaparib Sensitive: A2 - Guideline	olaparib Sensitive: A2 - Guideline
BRCA2 mutation BRCA2 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA2 mutation BRCA2 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	talazoparib Sensitive: A2 - Guideline	talazoparib Sensitive: A2 - Guideline
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	talazoparib Sensitive: A2 - Guideline	talazoparib Sensitive: A2 - Guideline
No biomarker No biomarker	Triple Negative Breast Cancer Triple Negative Breast Cancer	No biomarker No biomarker	Triple Negative Breast Cancer Triple Negative Breast Cancer	carboplatin Sensitive: A2 - Guideline	carboplatin Sensitive: A2 - Guideline
BRCA2 mutation BRCA2 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA2 mutation BRCA2 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	PARP inhibitor Sensitive: A2 - Guideline	PARP inhibitor Sensitive: A2 - Guideline
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	PARP inhibitor Sensitive: A2 - Guideline	PARP inhibitor Sensitive: A2 - Guideline
BRCA2 mutation BRCA2 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA2 mutation BRCA2 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	doxorubicin hydrochloride Sensitive: A2 - Guideline	doxorubicin hydrochloride Sensitive: A2 - Guideline
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	doxorubicin hydrochloride Sensitive: A2 - Guideline	doxorubicin hydrochloride Sensitive: A2 - Guideline
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	paclitaxel Sensitive: A2 - Guideline	paclitaxel Sensitive: A2 - Guideline
PD-L1 expression PD-L1 expression	Triple Negative Breast Cancer Triple Negative Breast Cancer	PD-L1 expression PD-L1 expression	Triple Negative Breast Cancer Triple Negative Breast Cancer	Immunotherapy Sensitive: A2 - Guideline	Immunotherapy Sensitive: A2 - Guideline
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	CaT Sensitive: B - Late Trials	CaT Sensitive: B - Late Trials
No biomarker No biomarker	Triple Negative Breast Cancer Triple Negative Breast Cancer	No biomarker No biomarker	Triple Negative Breast Cancer Triple Negative Breast Cancer	IPI-549 Sensitive: B - Late Trials	IPI-549 Sensitive: B - Late Trials
AKT1 mutation AKT1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	AKT1 mutation AKT1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	GDC-0068 Sensitive: B - Late Trials	GDC-0068 Sensitive: B - Late Trials
PTEN mutation PTEN mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	PTEN mutation PTEN mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	GDC-0068 Sensitive: B - Late Trials	GDC-0068 Sensitive: B - Late Trials
PD-L1 overexpression PD-L1 overexpression	Triple Negative Breast Cancer Triple Negative Breast Cancer	PD-L1 overexpression PD-L1 overexpression	Triple Negative Breast Cancer Triple Negative Breast Cancer	pembrolizumab Sensitive: B - Late Trials	pembrolizumab Sensitive: B - Late Trials
PIK3CA mutation PIK3CA mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	PIK3CA mutation PIK3CA mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	GDC-0068 Sensitive: B - Late Trials	GDC-0068 Sensitive: B - Late Trials
BRCA2 mutation BRCA2 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA2 mutation BRCA2 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	carboplatin + paclitaxel Sensitive: B - Late Trials	carboplatin + paclitaxel Sensitive: B - Late Trials
BRCA2 mutation BRCA2 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA2 mutation BRCA2 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	ABT-888 Sensitive: B - Late Trials	ABT-888 Sensitive: B - Late Trials
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	ABT-888 Sensitive: B - Late Trials	ABT-888 Sensitive: B - Late Trials
CDKN2B mutation CDKN2B mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	CDKN2B mutation CDKN2B mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	atezolizumab Sensitive: B - Late Trials	atezolizumab Sensitive: B - Late Trials
CDKN2A mutation CDKN2A mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	CDKN2A mutation CDKN2A mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	atezolizumab Sensitive: B - Late Trials	atezolizumab Sensitive: B - Late Trials
BRCA2 mutation BRCA2 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA2 mutation BRCA2 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	atezolizumab Sensitive: B - Late Trials	atezolizumab Sensitive: B - Late Trials
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	atezolizumab Sensitive: B - Late Trials	atezolizumab Sensitive: B - Late Trials
ER positive + HER-2 negative ER positive + HER-2 negative	Triple Negative Breast Cancer Triple Negative Breast Cancer	ER positive + HER-2 negative ER positive + HER-2 negative	Triple Negative Breast Cancer Triple Negative Breast Cancer	cyclophosphamide oral + thiotepa Sensitive: B - Late Trials	cyclophosphamide oral + thiotepa Sensitive: B - Late Trials
TMB-H + PD-L1 expression TMB-H + PD-L1 expression	Triple Negative Breast Cancer Triple Negative Breast Cancer	TMB-H + PD-L1 expression TMB-H + PD-L1 expression	Triple Negative Breast Cancer Triple Negative Breast Cancer	atezolizumab Sensitive: B - Late Trials	atezolizumab Sensitive: B - Late Trials
No biomarker No biomarker	Triple Negative Breast Cancer Triple Negative Breast Cancer	No biomarker No biomarker	Triple Negative Breast Cancer Triple Negative Breast Cancer	trilaciclib Sensitive: B - Late Trials	trilaciclib Sensitive: B - Late Trials
No biomarker No biomarker	Triple Negative Breast Cancer Triple Negative Breast Cancer	No biomarker No biomarker	Triple Negative Breast Cancer Triple Negative Breast Cancer	CT7001 Sensitive: B - Late Trials	CT7001 Sensitive: B - Late Trials
HR positive HR positive	Triple Negative Breast Cancer Triple Negative Breast Cancer	HR positive HR positive	Triple Negative Breast Cancer Triple Negative Breast Cancer	olaparib Sensitive: C1 - Off-label	olaparib Sensitive: C1 - Off-label
HRD HRD	Triple Negative Breast Cancer Triple Negative Breast Cancer	HRD HRD	Triple Negative Breast Cancer Triple Negative Breast Cancer	olaparib Sensitive: C1 - Off-label	olaparib Sensitive: C1 - Off-label
BRCA2 mutation BRCA2 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA2 mutation BRCA2 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	niraparib Sensitive: C1 - Off-label	niraparib Sensitive: C1 - Off-label
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	niraparib Sensitive: C1 - Off-label	niraparib Sensitive: C1 - Off-label
TMB-H TMB-H	Triple Negative Breast Cancer Triple Negative Breast Cancer	TMB-H TMB-H	Triple Negative Breast Cancer Triple Negative Breast Cancer	pembrolizumab Sensitive: C1 - Off-label	pembrolizumab Sensitive: C1 - Off-label
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	rucaparib Sensitive: C1 - Off-label	rucaparib Sensitive: C1 - Off-label
PD-L1 expression PD-L1 expression	Triple Negative Breast Cancer Triple Negative Breast Cancer	PD-L1 expression PD-L1 expression	Triple Negative Breast Cancer Triple Negative Breast Cancer	durvalumab Sensitive: C1 - Off-label	durvalumab Sensitive: C1 - Off-label
BRCA2 mutation BRCA2 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA2 mutation BRCA2 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	pamiparib Sensitive: C1 - Off-label	pamiparib Sensitive: C1 - Off-label
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	pamiparib Sensitive: C1 - Off-label	pamiparib Sensitive: C1 - Off-label
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	tislelizumab + pamiparib Sensitive: C2 – Inclusion Criteria	tislelizumab + pamiparib Sensitive: C2 – Inclusion Criteria
PTEN-L PTEN-L	Triple Negative Breast Cancer Triple Negative Breast Cancer	PTEN-L PTEN-L	Triple Negative Breast Cancer Triple Negative Breast Cancer	GDC-0068 Sensitive: C2 – Inclusion Criteria	GDC-0068 Sensitive: C2 – Inclusion Criteria
AR positive AR positive	Triple Negative Breast Cancer Triple Negative Breast Cancer	AR positive AR positive	Triple Negative Breast Cancer Triple Negative Breast Cancer	enzalutamide Sensitive: C2 – Inclusion Criteria	enzalutamide Sensitive: C2 – Inclusion Criteria
PD-L1 expression PD-L1 expression	Triple Negative Breast Cancer Triple Negative Breast Cancer	PD-L1 expression PD-L1 expression	Triple Negative Breast Cancer Triple Negative Breast Cancer	avelumab Sensitive: C2 – Inclusion Criteria	avelumab Sensitive: C2 – Inclusion Criteria
PD-L1 expression PD-L1 expression	Triple Negative Breast Cancer Triple Negative Breast Cancer	PD-L1 expression PD-L1 expression	Triple Negative Breast Cancer Triple Negative Breast Cancer	olaparib + durvalumab + cediranib Sensitive: C2 – Inclusion Criteria	olaparib + durvalumab + cediranib Sensitive: C2 – Inclusion Criteria
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	olaparib + durvalumab Sensitive: C2 – Inclusion Criteria	olaparib + durvalumab Sensitive: C2 – Inclusion Criteria
HRD HRD	Triple Negative Breast Cancer Triple Negative Breast Cancer	HRD HRD	Triple Negative Breast Cancer Triple Negative Breast Cancer	tislelizumab Sensitive: C2 – Inclusion Criteria	tislelizumab Sensitive: C2 – Inclusion Criteria
BRCA2 mutation BRCA2 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA2 mutation BRCA2 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	tislelizumab Sensitive: C2 – Inclusion Criteria	tislelizumab Sensitive: C2 – Inclusion Criteria
BRCA2 mutation BRCA2 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA2 mutation BRCA2 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	durvalumab Sensitive: C2 – Inclusion Criteria	durvalumab Sensitive: C2 – Inclusion Criteria
PD-L1 expression PD-L1 expression	Triple Negative Breast Cancer Triple Negative Breast Cancer	PD-L1 expression PD-L1 expression	Triple Negative Breast Cancer Triple Negative Breast Cancer	toripalimab Sensitive: C2 – Inclusion Criteria	toripalimab Sensitive: C2 – Inclusion Criteria
TLE3 expression TLE3 expression	Triple Negative Breast Cancer Triple Negative Breast Cancer	TLE3 expression TLE3 expression	Triple Negative Breast Cancer Triple Negative Breast Cancer	eribulin mesylate Sensitive: C3 – Early Trials	eribulin mesylate Sensitive: C3 – Early Trials
AKT1 amplification AKT1 amplification	Triple Negative Breast Cancer Triple Negative Breast Cancer	AKT1 amplification AKT1 amplification	Triple Negative Breast Cancer Triple Negative Breast Cancer	BKM120 Sensitive: C3 – Early Trials	BKM120 Sensitive: C3 – Early Trials
AKT1 E17K AKT1 E17K	Triple Negative Breast Cancer Triple Negative Breast Cancer	AKT1 E17K AKT1 E17K	Triple Negative Breast Cancer Triple Negative Breast Cancer	BKM120 Sensitive: C3 – Early Trials	BKM120 Sensitive: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	PIK3CA mutation PIK3CA mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	everolimus Sensitive: C3 – Early Trials	everolimus Sensitive: C3 – Early Trials
PALB2 mutation PALB2 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	PALB2 mutation PALB2 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	everolimus Sensitive: C3 – Early Trials	everolimus Sensitive: C3 – Early Trials
BRCA2 mutation BRCA2 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA2 mutation BRCA2 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	gemcitabine + eribulin mesylate Resistant: C3 – Early Trials	gemcitabine + eribulin mesylate Resistant: C3 – Early Trials
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	gemcitabine + eribulin mesylate Resistant: C3 – Early Trials	gemcitabine + eribulin mesylate Resistant: C3 – Early Trials
AR positive AR positive	Triple Negative Breast Cancer Triple Negative Breast Cancer	AR positive AR positive	Triple Negative Breast Cancer Triple Negative Breast Cancer	palbociclib Sensitive: C3 – Early Trials	palbociclib Sensitive: C3 – Early Trials
CD47 overexpression CD47 overexpression	Triple Negative Breast Cancer Triple Negative Breast Cancer	CD47 overexpression CD47 overexpression	Triple Negative Breast Cancer Triple Negative Breast Cancer	VT1021 Sensitive: C3 – Early Trials	VT1021 Sensitive: C3 – Early Trials
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	pembrolizumab + niraparib Sensitive: C3 – Early Trials	pembrolizumab + niraparib Sensitive: C3 – Early Trials
BRCA2 mutation BRCA2 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA2 mutation BRCA2 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	pembrolizumab + niraparib Sensitive: C3 – Early Trials	pembrolizumab + niraparib Sensitive: C3 – Early Trials
PD-L1 underexpression PD-L1 underexpression	Triple Negative Breast Cancer Triple Negative Breast Cancer	PD-L1 underexpression PD-L1 underexpression	Triple Negative Breast Cancer Triple Negative Breast Cancer	atezolizumab + RG6180 Sensitive: C3 – Early Trials	atezolizumab + RG6180 Sensitive: C3 – Early Trials
PTEN mutation PTEN mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	PTEN mutation PTEN mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	pembrolizumab Resistant: C3 – Early Trials	pembrolizumab Resistant: C3 – Early Trials
PTEN mutation PTEN mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	PTEN mutation PTEN mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	atezolizumab Resistant: C3 – Early Trials	atezolizumab Resistant: C3 – Early Trials
TMB-H TMB-H	Triple Negative Breast Cancer Triple Negative Breast Cancer	TMB-H TMB-H	Triple Negative Breast Cancer Triple Negative Breast Cancer	atezolizumab Sensitive: C3 – Early Trials	atezolizumab Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Triple Negative Breast Cancer Triple Negative Breast Cancer	PD-L1 overexpression PD-L1 overexpression	Triple Negative Breast Cancer Triple Negative Breast Cancer	olaparib Sensitive: C3 – Early Trials	olaparib Sensitive: C3 – Early Trials
FOXA1 overexpression FOXA1 overexpression	Triple Negative Breast Cancer Triple Negative Breast Cancer	FOXA1 overexpression FOXA1 overexpression	Triple Negative Breast Cancer Triple Negative Breast Cancer	carboplatin + docetaxel Resistant: C3 – Early Trials	carboplatin + docetaxel Resistant: C3 – Early Trials
AR overexpression AR overexpression	Triple Negative Breast Cancer Triple Negative Breast Cancer	AR overexpression AR overexpression	Triple Negative Breast Cancer Triple Negative Breast Cancer	TAK 700 Sensitive: C3 – Early Trials	TAK 700 Sensitive: C3 – Early Trials
CD8-H CD8-H	Triple Negative Breast Cancer Triple Negative Breast Cancer	CD8-H CD8-H	Triple Negative Breast Cancer Triple Negative Breast Cancer	pembrolizumab Sensitive: C3 – Early Trials	pembrolizumab Sensitive: C3 – Early Trials
MYC amplification MYC amplification	Triple Negative Breast Cancer Triple Negative Breast Cancer	MYC amplification MYC amplification	Triple Negative Breast Cancer Triple Negative Breast Cancer	talazoparib Resistant: C3 – Early Trials	talazoparib Resistant: C3 – Early Trials
CD36 overexpression CD36 overexpression	Triple Negative Breast Cancer Triple Negative Breast Cancer	CD36 overexpression CD36 overexpression	Triple Negative Breast Cancer Triple Negative Breast Cancer	VT1021 Sensitive: C3 – Early Trials	VT1021 Sensitive: C3 – Early Trials
AR positive AR positive	Triple Negative Breast Cancer Triple Negative Breast Cancer	AR positive AR positive	Triple Negative Breast Cancer Triple Negative Breast Cancer	pembrolizumab Sensitive: C3 – Early Trials	pembrolizumab Sensitive: C3 – Early Trials
MMP17 expression + EGFR expression + RB1 expression MMP17 expression + EGFR expression + RB1 expression	Triple Negative Breast Cancer Triple Negative Breast Cancer	MMP17 expression + EGFR expression + RB1 expression MMP17 expression + EGFR expression + RB1 expression	Triple Negative Breast Cancer Triple Negative Breast Cancer	erlotinib + palbociclib Sensitive: C3 – Early Trials	erlotinib + palbociclib Sensitive: C3 – Early Trials
MMP17 expression + EGFR expression + RB1 expression MMP17 expression + EGFR expression + RB1 expression	Triple Negative Breast Cancer Triple Negative Breast Cancer	MMP17 expression + EGFR expression + RB1 expression MMP17 expression + EGFR expression + RB1 expression	Triple Negative Breast Cancer Triple Negative Breast Cancer	erlotinib Resistant: C3 – Early Trials	erlotinib Resistant: C3 – Early Trials
PD-L1 expression + CD68 positive PD-L1 expression + CD68 positive	Triple Negative Breast Cancer Triple Negative Breast Cancer	PD-L1 expression + CD68 positive PD-L1 expression + CD68 positive	Triple Negative Breast Cancer Triple Negative Breast Cancer	durvalumab Sensitive: C3 – Early Trials	durvalumab Sensitive: C3 – Early Trials
PD-L1 amplification PD-L1 amplification	Triple Negative Breast Cancer Triple Negative Breast Cancer	PD-L1 amplification PD-L1 amplification	Triple Negative Breast Cancer Triple Negative Breast Cancer	durvalumab Sensitive: C3 – Early Trials	durvalumab Sensitive: C3 – Early Trials

Triple Negative Breast Cancer

Associations(214)

Associations
(214)